Integra CFO granted 111,179 RSUs, covers taxes

INTEGRA LIFESCIENCES HOLDINGS CORP EVP & Chief Financial Officer Lea Daniels Knight reported a compensation-related equity grant and routine tax withholding.

Accepted by SEC EDGAR 03/12/2026 - 05:16 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

INTEGRA LIFESCIENCES HOLDINGS CORP EVP & Chief Financial Officer Lea Daniels Knight reported a compensation-related equity grant and routine tax withholding. She received 111,179 restricted stock units linked to common stock, which vest 33% on the first and second anniversaries of the March 11, 2026 grant date and 34% on the third anniversary.

On the same date, 8,089 shares of common stock were disposed of at $9.61 per share to cover tax obligations, and she now directly holds 50,489 common shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Knight Lea Daniels

Role EVP & Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	111,179	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	8,089	$9.61	$78K

Holdings After Transaction: Restricted Stock Units — 111,179 contracts (Direct); Common Stock — 50,489 shares (Direct)

Holdings Before and After: Restricted Stock Units, 0 to 111,179 contracts (Direct); Common Stock, 58,578 to 50,489 shares (Direct)

Footnotes (1)

1. F1. The award was a restricted stock unit award which will vest 33% on the first and second anniversaries and 34% on the third anniversary of the grant date of 3/11/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Integra Lifesciences (IART) CFO Lea Daniels Knight report in this Form 4?

She reported a grant of 111,179 restricted stock units and a related tax-withholding share disposition. The filing shows equity-based compensation and routine share withholding to satisfy tax obligations, not an open-market stock purchase or sale.

How many restricted stock units did the Integra Lifesciences (IART) CFO receive?

She received 111,179 restricted stock units tied to common stock. These units represent a form of stock-based compensation and will convert into common shares as they vest over the specified three-year schedule beginning on March 11, 2026.

What is the vesting schedule for the CFO’s 111,179 RSUs at Integra Lifesciences (IART)?

The restricted stock units vest 33% on the first anniversary and 33% on the second anniversary of March 11, 2026, then 34% on the third anniversary. This staggered schedule encourages long-term alignment with shareholder interests.

Why were 8,089 Integra Lifesciences (IART) shares disposed of in this Form 4?

The 8,089 common shares were disposed of at $9.61 per share to satisfy tax liabilities tied to the equity award. This F-code transaction is tax withholding by delivering securities, not an open-market sale decision.

How many Integra Lifesciences (IART) shares does the CFO hold after these transactions?

Following the reported tax-withholding disposition, Lea Daniels Knight directly holds 50,489 shares of Integra Lifesciences common stock. This figure reflects her remaining direct ownership after 8,089 shares were delivered to cover tax obligations.

Are the Integra Lifesciences (IART) CFO’s Form 4 transactions open-market trades?

No, the filing shows a grant of restricted stock units and a tax-withholding disposition. The RSU grant is compensation, and the F-code share delivery covers tax liabilities, rather than discretionary open-market buying or selling of shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Knight Lea Daniels

(Last) (First) (Middle)

1100 CAMPUS ROAD

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		F		8,089	D	$9.61	50,489	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	03/11/2026		A		111,179		(1)	(1)	Common Stock	111,179	$0	111,179	D

Explanation of Responses:

1. The award was a restricted stock unit award which will vest 33% on the first and second anniversaries and 34% on the third anniversary of the grant date of 3/11/2026.

Remarks:

	/s/ Michael D. Hutchinson; Attorney-in-Fact for Lea Knight	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.